Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-045201
Filing Date
2024-11-13
Accepted
2024-11-13 17:16:29
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 706835
2 ex31-1.htm EX-31.1 11142
3 ex31-2.htm EX-31.2 11004
4 ex32-1.htm EX-32.1 8057
5 form10-q_001.jpg GRAPHIC 19140
  Complete submission text file 0001493152-24-045201.txt   4078145

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20240930.xsd EX-101.SCH 32860
7 XBRL CALCULATION FILE mtnb-20240930_cal.xml EX-101.CAL 51099
8 XBRL DEFINITION FILE mtnb-20240930_def.xml EX-101.DEF 86802
9 XBRL LABEL FILE mtnb-20240930_lab.xml EX-101.LAB 297206
10 XBRL PRESENTATION FILE mtnb-20240930_pre.xml EX-101.PRE 237970
73 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 515666
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 241455678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)